PC化疗联合吉非替尼对EGFR突变阳性晚期肺腺癌患者疾病控制率及生存质量的影响

目的探讨PC化疗联合吉非替尼对表皮生长因子受体突变阳性晚期肺腺癌患者疾病控制率及生存质量的影响.方法将90例表皮生长因子受体突变阳性晚期肺腺癌患者按随机数字表法分为两组,每组45例.两组均予以PC化疗,研究组在此基础上联合吉非替尼治疗,统计两组临床疗效、不良反应发生率,比较两组治疗前后血清癌胚抗原、糖类抗原153、糖类抗原125、糖类抗原199水平及癌症患者生存质量评定量表评分.结果研究组疾病控制率为86.7%,对照组为66.7%,研究组显著高于对照组(P<0.05).治疗后两组血清癌胚抗原、糖类抗原153、糖类抗原125、糖类抗原199水平均较治疗前显著降低(P<0.01),癌症患者生存质量评定量表评分较治疗前显著升高(P<0.01),研究组显著优于对照组(P<0.01).两组不良反应发生率比较差异无统计学意义(P>0.05).结论PC化疗联合吉非替尼治疗表皮生长因子受体突变阳性晚期肺腺癌能明显提高疾病控制率,降低血清肿瘤标志物水平,提高患者生存质量,安全性高.

Effect of PC chemotherapy combined with gefitinib on disease control rate and quality of life in patients with EGFR mutation-positive advanced lung adenocarcinoma

Objective To investigate the effect of PC chemotherapy combined with gefitinib on disease control rate and quality of life in patients with EGFR mutation-positive advanced lung adenocarcinoma.Methods A total of 90 patients with advanced EGFR mutation-positive lung adenocarcinoma were enrolled and divided into two groups according to the random number table method,45 cases in each group.After treatment with chemotherapy,the study group was treated with gefitinib on the basis of the control group.The efficacy and adverse reaction rate of the two groups were compared.The levels of serum carcinoembryonic antigen,carbohydrate antigen 153,carbohydrate antigen 125,carbohydrate antigen 199 and the quality of life of cancer patients were compared before and after treatment in the two groups.Results The disease control rate of the study group was 86.7%,higher than that of the control group(66.7%)(P<0.05).The serum levels of CEA,CA153,CA125 and CA199 were lower than those before treatment(P<0.01).The EORTC-QLQ-C30 score of cancer patients was significantly higher than before treatment(P<0.01),and the study group was significantly better than the control group(P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions PC chemotherapy combined with gefitinib in treatment of EGFR mutation-positive advanced lung adenocarcinoma can significantly improve disease control rate,reduce serum tumor marker levels,improve patient quality of life,and have high safety.